Open Access

Introduction: SGLT2 inhibitors beyond glycemic control.

Topic: Heart Failure
Sponsored by Charité Berlin - Supported by an unrestricted educational grant from The Boehringer Ingelheim and Lilly Alliance

Congress Presentation

About the speaker

Doctor Shelley Zieroth

University of Manitoba, Winnipeg (Canada)
55 presentations
3 followers

5 more presentations in this session

Impact of SGLT2 inhibitors on CV mortality, HF hospitalizations and clinical stability.

Speaker: Professor M. Packer (Dallas, US)

Thumbnail

Renal benefits of SGLT2 inhibitors in HF patients.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Thumbnail

Effects of SGLT2 inhibitors on quality of life in HF.

Speaker: Professor J. Butler (Dallas, US)

Thumbnail

Safety of SGLT2 inhibitors with a focus on genital mycotic infections.

Speaker: Professor G. Filippatos (Athens, GR)

Thumbnail

Conclusion.

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Access the full session

SGLT2 inhibition in heart failure: what have we learned so far?

Speakers: Doctor S. Zieroth, Professor M. Packer, Professor F. Zannad, Professor J. Butler, Professor G. Filippatos...
Thumbnail

About the event

Image

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations